S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 172.5 HKD -3.42% Market Closed
Market Cap: 38.4B HKD
Have any thoughts about
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?
Write Note

Net Margin
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

-12.4%
Current
-25%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.4%
=
Net Income
-232.8m
/
Revenue
1.9B

Net Margin Across Competitors

Country CN
Market Cap 38.4B HKD
Net Margin
-12%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View

Market Cap
38.4B HKD
Industry
Biotechnology

Nestled in the vibrant economic landscape of China, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. emerges as a prominent figure within the biopharmaceutical industry. Founded as a subsidiary of the larger pharmaceutical umbrella of Sichuan Kelun Pharmaceutical Co., Ltd., the company leverages its parent's extensive network and expertise to carve its niche in an ever-evolving market. Kelun-Biotech focuses on innovation in drug development, particularly in biologics and complex generics. This focus allows it to produce high-value pharmaceuticals that address urgent medical needs, spanning across treatments for oncology, immunological disorders, and other critical health segments. Its dedication to cutting-edge research and development is evident in the substantial investments it channels into its laboratories and collaborations with leading research institutions, both domestically and internationally. The company's revenue model pivots around the commercialization of its proprietary drugs and partnerships with multinational pharmaceutical firms, where it contributes its research prowess to joint ventures. By positioning itself as a leader in the biologics sector, Kelun-Biotech capitalizes on the growing demand for biosimilars and innovative therapies in the global market. Its strategy to penetrate international markets is further bolstered by strategic alliances and compliance with stringent global regulatory approvals, enhancing its credibility and reach. These endeavors not only drive its revenue growth but also reinforce its mission to deliver high-quality, affordable healthcare solutions worldwide, making Kelun-Biotech an influential player in addressing global health challenges through pharmaceutical excellence.

Intrinsic Value
102.03 HKD
Overvaluation 41%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-12.4%
=
Net Income
-232.8m
/
Revenue
1.9B
What is the Net Margin of Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?

Based on Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of -12.4%.